{
  "meta": {
    "timestamp": "2025-01-06T11:26:54.730089",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "AbCellera Biologics Inc",
      "symbol": "ABCL",
      "analysis": {
        "historical": {
          "risk_score": 50,
          "key_risks": [
            "Dependence on Partnerships",
            "Regulatory Challenges",
            "Market Competition",
            "COVID-19 Impact",
            "Patent Disputes"
          ],
          "controversies": [
            "Patent litigation with Berkeley Lights"
          ],
          "environmental_issues": [],
          "social_issues": [],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 75
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "abcl-10k_20221231.htm - SEC.gov",
              "snippet": "AbCellera Biologics Inc. ... We understand that the challenges and opportunities in biotechnology are different from those of other sectors. The process of developing drugs is complex and highly regulated, and as a result product development timelines are long. ... Because of the inherently complex regulatory regime governing the testing ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758705+00:00",
              "published_date": null,
              "source_hash": "b1ae27d02f57483187fc83d41304efa4"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - Governance - Governance Documents",
              "snippet": "AbCellera has established various ways for individuals to raise matters of concern regarding the conduct of Company officials, or financial, ethical, legal or other issues related to the way the Company is conducting its business. One avenue for raising such issues is the Confidential and Anonymous Financial Concern Hotline (the Hotline).",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758824+00:00",
              "published_date": null,
              "source_hash": "b108619f29ceade083d23bea1536e948"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - Investor Relations",
              "snippet": "AbCellera's engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. View ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758842+00:00",
              "published_date": null,
              "source_hash": "623ce3dc38118abaede15bf7fc10d01c"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. (Form: 10-K, Received: 03/30/2021 18:07:05)",
              "snippet": "AbCellera Biologics Inc. (Exact name of Registrant as specified in its Charter) ... However, some of the challenges faced with many immunization-based approaches are (i) difficulty in raising a strong immune response against poorly immunogenic targets, (ii) traditional screening methods that restrict immunization and discovery to rodents and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758855+00:00",
              "published_date": null,
              "source_hash": "b5ec5d0f210add4d928e513a67a1c78e"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - Financials - SEC Filings",
              "snippet": "Find AbCellera (NASDAQ: ABCL) financial information and SEC filings.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758866+00:00",
              "published_date": null,
              "source_hash": "8a131c64bc9d6d0b69f69e4ab4d1e821"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc (ABCL) Q3 2024 Earnings Call Highlights ...",
              "snippet": "AbCellera Biologics Inc (NASDAQ:ABCL) reported a net loss of approximately $51 million for the quarter, compared to a loss of nearly $29 million in the same quarter last year.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758877+00:00",
              "published_date": null,
              "source_hash": "806cfc4f6f93049f4d6ac68b7ebb2c30"
            },
            {
              "url": "",
              "title": "AbCellera Biologics, Inc. ESG Risk Rating - Sustainalytics",
              "snippet": "AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758888+00:00",
              "published_date": null,
              "source_hash": "2ff91cce335267b929770b577e9f7d33"
            },
            {
              "url": "",
              "title": "AbCellera Biologics: Still A Concept Stock - Seeking Alpha",
              "snippet": "AbCellera Biologics ended the third quarter with $670 million of cash and marketable securities on its balance sheet after posting a net loss of $51.1 million for the third quarter. The company ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649630+00:00",
              "published_date": null,
              "source_hash": "05b897c60e1494168bf91f4f0249228c"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - AbCellera to Report Third Quarter 2024 ...",
              "snippet": "AbCellera (Nasdaq: ABCL) will announce its third quarter 2024 financial results on Monday, November 4, 2024, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day. A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera's Investor Relations website . A replay will be available through the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758909+00:00",
              "published_date": null,
              "source_hash": "6e3d410d8ca052e911651b7e13d29e5d"
            },
            {
              "url": "",
              "title": "AbCellera-Discovered Antibody, Bamlanivimab, Administered with ...",
              "snippet": "AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines . Read article. November 1, 2023 . Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology . Read article. March 22, 2023 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:30.758920+00:00",
              "published_date": null,
              "source_hash": "89a76482706bd77526698dcd6511c0ca"
            },
            {
              "url": "",
              "title": "AbCellera Biologics: Still A Concept Stock",
              "snippet": "AbCellera Biologics Inc. shifts focus to developing wholly owned candidates and trades near net cash on its balance sheet. Find out why ABCL stock is a Hold.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:41.257964+00:00",
              "published_date": "2024-12-23T20:40:00+00:00",
              "source_hash": "de34e9726b6c656cc453ca47d480a0b3"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc (ABCL) Stock: More Robust Than the Numbers Suggest?",
              "snippet": "AbCellera Biologics Inc (ABCL) stock saw a modest uptick, ending the day at $3.13 which represents a slight increase of $0.10 or 3.30% from the prior close of $3.03. The stock opened at $3.05 and touched a low of $3.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:41.258065+00:00",
              "published_date": "2025-01-04T14:54:00+00:00",
              "source_hash": "dbd7fa25679dd6cfae68610700c0a522"
            },
            {
              "url": "",
              "title": "Why Did The Benchmark Company Give AbCellera Biologics Inc (ABCL) Stock Hold Rating?",
              "snippet": "AbCellera Biologics Inc (ABCL) stock saw a modest uptick, ending the day at $2.95 which represents a slight increase of $0.03 or 1.03% from the prior close of $2.92. The stock opened at $2.93 and touched a low of $2.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:41.258095+00:00",
              "published_date": "2024-12-25T15:58:00+00:00",
              "source_hash": "718ffff7d58b8483b812861b29fdb7ca"
            },
            {
              "url": "",
              "title": "AI drug discovery biotech AbCellera eyes record IPO",
              "snippet": "AbCellera Biologics has been in the spotlight since ... with Lilly for bamlanivimab (LY-CoV555), which was approved by the FDA and Canadian regulator for emergency use as treatment for mild ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc regulatory challenges FDA",
              "retrieved_at": "2025-01-06T18:26:33.141261+00:00",
              "published_date": "2020-12-08T00:00:00+00:00",
              "source_hash": "99d04cac7199a7098e65bbd70f7ae549"
            },
            {
              "url": "",
              "title": "Is AbCellera Biologics Inc. (ABCL) the Penny Stock with the Biggest Upside Potential According to Analysts?",
              "snippet": "Let's look at where AbCellera Biologics Inc. (ABCL) stands against other penny stocks with the biggest upside potential. The Federal Reserve slashed interest rates by a half point in September ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:41.258121+00:00",
              "published_date": "2024-10-16T13:25:00+00:00",
              "source_hash": "ce4e96b9e4083c5ffd17dbaea281c694"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - Prelude Therapeutics and AbCellera Enter ...",
              "snippet": "About AbCellera Biologics Inc. AbCellera is breaking the barriers of conventional antibody drug discovery to bring better medicines to patients, sooner. AbCellera's engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649454+00:00",
              "published_date": null,
              "source_hash": "5d31b68aba35b0f90427fde43ecb0c2b"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - AbCellera and Lilly Expand Collaboration to ...",
              "snippet": "AbCellera (Nasdaq: ABCL) announced today that it has expanded its existing collaboration with Eli Lilly and Company (Lilly) to discover therapeutic antibodies for programs in immunology, cardiovascular disease, and neuroscience. The expansion builds upon the successful research collaboration established in March 2020, which included eight de novo programs for targets selected by Lilly and an ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649562+00:00",
              "published_date": null,
              "source_hash": "b6e2f99f799536c3a68604ba426fcf20"
            },
            {
              "url": "",
              "title": "AbCellera and Lilly broadens antibody discovery partnership - Yahoo Finance",
              "snippet": "AbCellera Biologics has broadened its partnership with Eli Lilly to discover therapeutic antibodies in immunology, cardiovascular disease and neuroscience programmes.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649577+00:00",
              "published_date": null,
              "source_hash": "7a615b3e6e2dffa55eefbff62874fb56"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - AbCellera Announces Collaboration with ...",
              "snippet": "Partnership combines AbCellera's AI-powered antibody discovery platform with Moderna's mRNA technology platform to accelerate the development of mRNA-encoded antibody therapeutics across multiple indications AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera's AI-powered ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649588+00:00",
              "published_date": null,
              "source_hash": "90a11be546efeb4fd9c367a390c4bb27"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Expands Partnership and Advances Pipeline",
              "snippet": "AbCellera Biologics ( ) has shared an update. AbCellera reported its Q3 2024 financial results, highlighting a strategic expansion with Eli Lilly for antibody discovery in key therapeutic areas.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649601+00:00",
              "published_date": null,
              "source_hash": "ac96afd00a0864413abce377df0e5ed6"
            },
            {
              "url": "",
              "title": "Prelude Therapeutics and AbCellera Enter Partnership to ... - Nasdaq",
              "snippet": "--Prelude Therapeutics Incorporated and AbCellera today announced a multi-year, multi-program partnership to discover, develop, and commercialize potentially first-in-class treatments for patients ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649610+00:00",
              "published_date": null,
              "source_hash": "8d99a6f14b45e786b956ba751fea7fc7"
            },
            {
              "url": "",
              "title": "Partners - AbCellera",
              "snippet": "Strategic Partnerships Making medicines together. We strategically partner with groups that have novel science and innovative technology to develop antibody-based medicines. Our Impact Making a difference for patients. Since 2015, we have worked with more than 40 partners on 100+ antibody drug programs, with 14 candidates reaching the clinic to date. 100+ Antibody DrugPrograms Started",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649621+00:00",
              "published_date": null,
              "source_hash": "5ff6519383adc44915a5015108151ef1"
            },
            {
              "url": "",
              "title": "AbCellera Biologics: Continuing To Expand Partnerships - Seeking Alpha",
              "snippet": "AbCellera Biologics Inc. saw a significant decline in revenue due to the end of the COVID-19 pandemic, but has a large cash hoard and continues to expand partnerships.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649638+00:00",
              "published_date": null,
              "source_hash": "a9a6fd5c3364fe99298efea58b132e56"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - AbCellera to Collaborate with Biogen to ...",
              "snippet": "AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. \"Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,\" said Murray McCutcheon, Ph.D ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:34.649648+00:00",
              "published_date": null,
              "source_hash": "98df4a01822804466de871f8ae9adcd2"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. (ABCL)",
              "snippet": "Sustainalytics' Controversies Research identifies companies involved in incidents and events that may negatively impact stakeholders, the environment or the company's operations. Controversies ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc partnership controversies",
              "retrieved_at": "2025-01-06T18:26:37.205799+00:00",
              "published_date": "2024-12-31T21:00:00+00:00",
              "source_hash": "c031a6c38880b61c13df9de8704a963e"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - AbCellera Announces that the U.S. Patent ...",
              "snippet": "PTAB rejects third request by Berkeley Lights for invalidation of AbCellera's U.S. patents AbCellera (Nasdaq: ABCL) today announced that the United States Patent and Trademark Office's Patent Trial and Appeal Board (PTAB) has ruled in favor of AbCellera in an Inter Partes Review (IPR) filed by Berkeley Lights, Inc. (Berkeley Lights) that challenged AbCellera's U.S. Patent No. 10,087,408 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746103+00:00",
              "published_date": null,
              "source_hash": "e58e750919e4e20e0a94acb4960f6630"
            },
            {
              "url": "",
              "title": "Abcellera Biologics Inc. v. Bruker Cellular Analysis, Inc. - Casetext",
              "snippet": "Read Abcellera Biologics Inc. v. Bruker Cellular Analysis, Inc., 20-cv-08624-JST, ... The present case is a consolidated action incorporating three patent infringement cases brought by Plaintiffs in the United States District Court for the District of Delaware in the summer of 2020. ... at *4. Essentially, the court in Bowmar Archery concluded ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746207+00:00",
              "published_date": null,
              "source_hash": "ffebbcf1c837b72b9c8b2c5be7cc6615"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. v. Bruker Cellular Analysis, Inc.",
              "snippet": "Read AbCellera Biologics Inc. v. Bruker Cellular Analysis, Inc., 20-cv-08624-JST (VKD), ... 2024 DISCOVERY DISPUTE RE DEFENDANT'S INTERROGATORY NO. 1. RE: DKT. NO. 250 ... is the same for multiple claims and multiple patents, AbCellera may so state and may group asserted claims and patents accordingly. Additionally, AbCellera need not describe ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746228+00:00",
              "published_date": null,
              "source_hash": "40770262832064ae69f4ba99f78dfb4a"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. v. Berkeley Lights, Inc. - Casetext",
              "snippet": "Read AbCellera Biologics Inc. v. Berkeley Lights, Inc., 20-cv-08624-JST, ... The parties dispute the construction of ten terms in asserted patents: five terms from each patent family. ... may be retained.\" '962 patent at 14:16-18. This dispute is essentially the same as the first part of the dispute as to the term \"chamber\" in the '408 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746242+00:00",
              "published_date": null,
              "source_hash": "43b43fde7068f550686f8340c29f6317"
            },
            {
              "url": "",
              "title": "AbCellera Antibody-Test Patents Case Against Bruker Is Tossed",
              "snippet": "A federal judge dismissed AbCellera Biologics Inc.'s lawsuit against Bruker Cellular Analysis Inc. over technology used to discover antibodies for preventing and treating diseases, finding it failed to offer enough evidence to show how Bruker's microfluidic devices infringe fifteen patents.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746255+00:00",
              "published_date": null,
              "source_hash": "cd6f4e7fdcd3ed6af79e34abd7ac31a7"
            },
            {
              "url": "",
              "title": "PDF",
              "snippet": "No. 10,087,408. Inventors need to contribute to conception of at least one claim of a patent. CardiAQ Valve Techs., Inc. v. Neovasc Inc., 708 F. App'x 654, 658 (Fed. Cir. 2017). Plaintiffs contend that the '408 patent and its progeny were conceived between September 2006 and October 2007. Ex. 2 at 17-18.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746267+00:00",
              "published_date": null,
              "source_hash": "49cde48830a3a348b9ec73607034d339"
            },
            {
              "url": "",
              "title": "Berkeley Lights, Inc. v. Abcellera Biologics Inc., 4:20-cv-05957 ...",
              "snippet": "Docket for Berkeley Lights, Inc. v. Abcellera Biologics Inc., ... COMPLAINT for Declaratory Judgment of Non-Infringement of U.S. Patent; Demand for Jury Trial against Abcellera Biologics Inc., Lineage Biosciences, Inc. (Filing fee $ 400.00, receipt number 0971-14855127.). ... In the attached order, the court addresses the procedure for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746280+00:00",
              "published_date": null,
              "source_hash": "9afe8c447ddc127a8020840c453ae529"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. et al v. Berkeley Lights, Inc.",
              "snippet": "Patent case filed on December 7, 2020 in the California Northern District Court. ... Abcellera Biologics Inc: Case Number: 4:2020cv08624: Filed: December 7, 2020: ... 120 STATUS REPORT Joint Status Report Regarding Discovery Dispute (Dkt. No. 109) by Abcellera Biologics Inc, The University of British Columbia. (Stops, Eric) (Filed on 8/24/2021) ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746291+00:00",
              "published_date": null,
              "source_hash": "f99e252643927ee08861dd8654995ca2"
            },
            {
              "url": "",
              "title": "AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds ...",
              "snippet": "In response to claims against the '408 patent, AbCellera and UBC opposed institution and after oral argument, the PTAB rejected all of Berkeley Lights' arguments and confirmed that all claims of AbCellera's '408 Patent are valid. ... About AbCellera Biologics Inc. AbCellera is a technology company that searches, decodes, and analyzes ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746304+00:00",
              "published_date": null,
              "source_hash": "c6f75831a39901d8a7e443ace39b098c"
            },
            {
              "url": "",
              "title": "AbCellera Biologics Inc. - AbCellera Files Patent Infringement Lawsuit ...",
              "snippet": "AbCellera is asking the Court for a declaration that defendant direct and indirectly infringed AbCellera's patents, and is further seeking damages along with a permanent injunction preventing the defendant from using AbCellera's patented inventions for internal discovery programs and from offering for sale or selling any instrument or device ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:38.746316+00:00",
              "published_date": null,
              "source_hash": "b569c042a039721982106676482e19c8"
            },
            {
              "url": "",
              "title": "Abcellera Biologics Inc (ABCL)",
              "snippet": "VANCOUVER, BC - AbCellera Biologics Inc. (NASDAQ:ABCL) convened its Annual Meeting of Shareholders on Thursday, where attendees voted on key proposals, including the election... ByInvesting.com ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "AbCellera Biologics Inc AbCellera Biologics Inc patent disputes",
              "retrieved_at": "2025-01-06T18:26:41.258144+00:00",
              "published_date": "2024-12-10T20:58:00+00:00",
              "source_hash": "7241cd1525fc616757672676f115537c"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "AbCellera Biologics Inc regulatory challenges FDA",
              "rationale": "Investigate potential regulatory hurdles and FDA interactions that could impact drug approvals",
              "priority": 1
            },
            {
              "category": "ethical_social",
              "query": "AbCellera Biologics Inc partnership controversies",
              "rationale": "Explore any disputes or ethical concerns related to AbCellera's partnerships with pharmaceutical companies",
              "priority": 2
            },
            {
              "category": "financial_legal",
              "query": "AbCellera Biologics Inc patent disputes",
              "rationale": "Identify any intellectual property conflicts or patent litigation that could affect the company's operations",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T11:26:54.730095",
        "data_confidence": 75,
        "pattern_confidence": null
      }
    }
  ]
}